All In Biotech

Drug Trial Radar · NCT01842607

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials

Last checked: Nov 20, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

651

Actual

Start

May 27, 2013

Primary completion

Mar 13, 2015

Study completion Mar 13, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.

Conditions

  • Asthma

Interventions

  • MepolizumabBiological

    Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site ReactionsTime frame: From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-last dose])

Locations

137 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Rolling Hills Estates, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Albany, Georgia

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Rochester, Minnesota

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Hershey, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Salt Lake City, Utah

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Mendoza, Argentina

  • GSK Investigational Site

    Mar del Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    Mar del Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    San Rafael, Mendoza Province, Argentina

  • GSK Investigational Site

    Rosario, Santa Fe Province, Argentina

  • GSK Investigational Site

    New Lambton, New South Wales, Australia

  • GSK Investigational Site

    Bedford Park, South Australia, Australia

  • GSK Investigational Site

    Clayton, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Winnipeg, Manitoba, Canada

  • GSK Investigational Site

    Hamilton, Ontario, Canada

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.